Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

John Davis

Writer

London, U.K
A journalist and editor for more than 30 years, John has a broad interest in pharmaceuticals-related health care policy and breakthroughs in scientific and medical research.  He has degrees in biology and biochemical pharmacology.
Advertisement
Set Alert for Articles By John Davis

Latest From John Davis

Pharma Executives Need Convincing About Value-Based Contracts

Pharma company executives have limited experience with value-based contracts, but those that have experience are happy with them, says a new PwC report.

Pricing Debate Pricing Strategies

More Is Better? UK Crowdfunding Platform Selects First Firms

Capital Cell's effort might be the beginning of a viable alternative to VC funding for budding biotech companies.

Financing United Kingdom

European CHMP Opinions And MAA Updates

A monthly-updated listing of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the European Union, and updates on EU marketing authorization changes recommended by the CHMP.

Performance Tracker Approvals

Pipeline Watch: Phase III Readouts For ADV7103, Pembrolizumab, Upadacitinib

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals

J&J's Guselkumab Nears Crowded EU Psoriasis Market After CHMP OK

Janssen-Cilag/MorphoSys's potential first-in-class psoriasis therapy has received a positive approval recommendation from Europe's top scientific advisory panel, and could become a blockbuster product despite the cluttered and changeable state of the dermatology sector.

Approvals Biologics

Alexion Restructuring Deemed A Necessary Evil

The painful cuts in the workforce and HQ relocation planned by the new executive team at Alexion may be necessary for the long-term health of the company.

Business Strategies Rare Diseases
See All
Advertisement
UsernamePublicRestriction

Register